{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:42:40Z","timestamp":1778672560633,"version":"3.51.4"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Antipsychotic drugs represent the most effective treatment for chronic psychotic disorders. The newer second generation drugs offer the advantage of fewer neurological side-effects compared to prior drugs, but many cause serious metabolic side-effects. The underlying physiology of these side-effects is not well-understood, but evidence exists to indicate that the sympathetic nervous system may play an important role. In order to examine this possibility further, we treated separate groups of adult female rats acutely with either the first generation antipsychotic drug haloperidol (0.1 or 1 mg\/kg) or the second generation drugs risperidone (0.25 or 2.5 mg\/kg), clozapine (2 or 20 mg\/kg), olanzapine (3 or 15 mg\/kg) or vehicle by intraperitoneal injection. Blood samples were collected prior to drug and then 30, 60, 120, and 180 mins after treatment. Plasma samples were assayed by HPLC-ED for levels of norepinephrine, epinephrine, and dopamine. Results confirmed that all antipsychotics increased peripheral catecholamines, although this was drug and dose dependent. For norepinephrine, haloperidol caused the smallest maximum increase (+158%], followed by risperidone (+793%), olanzapine (+952%) and clozapine (+1,684%). A similar pattern was observed for increases in epinephrine levels by haloperidol (+143%], olanzapine (+529%), risperidone (+617%) then clozapine (+806%). Dopamine levels increased moderately with olanzapine [+174%], risperidone [+271%], and clozapine [+430%]. Interestingly, levels of the catecholamines did not correlate strongly with each other prior to treatment at baseline, but were increasingly correlated after treatment as time proceeded. The results demonstrate antipsychotics can potently regulate peripheral catecholamines, in a manner consistent with their metabolic liability.<\/jats:p>","DOI":"10.3389\/fpsyt.2020.617428","type":"journal-article","created":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T06:22:43Z","timestamp":1606803763000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Differential Effects of Acute Treatment With Antipsychotic Drugs on Peripheral Catecholamines"],"prefix":"10.3389","volume":"11","author":[{"given":"Heidi N.","family":"Boyda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanzo A.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lurdes","family":"Tse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ric M.","family":"Procyshyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica W. Y.","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David D.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Honer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alasdair M.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2165\/00023210-200721090-00001","article-title":"Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia","volume":"21","author":"Honer","year":"2007","journal-title":"CNS Drugs."},{"key":"B2","doi-asserted-by":"publisher","first-page":"566","DOI":"10.4088\/JCP.08m04912gre","article-title":"Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients","volume":"71","author":"Procyshyn","year":"2010","journal-title":"J Clin Psychiatry."},{"key":"B3","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s40266-018-0579-6","article-title":"A review of the pharmacological and clinical profile of newer atypical antipsychotics as treatments for bipolar disorder: considerations for use in older patients","volume":"35","author":"Vasudev","year":"2018","journal-title":"Drugs Aging."},{"key":"B4","doi-asserted-by":"publisher","first-page":"710","DOI":"10.2174\/1570159X16666180813155017","article-title":"Psychopharmacological treatment of Obsessive-Compulsive Disorder (OCD)","volume":"17","author":"Del Casale","year":"2019","journal-title":"Curr Neuropharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s40263-014-0162-6","article-title":"Role of atypical antipsychotics in the treatment of generalized anxiety disorder","volume":"28","author":"Hershenberg","year":"2014","journal-title":"CNS Drugs."},{"key":"B6","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1080\/24750573.2018.1458429","article-title":"The utility of psychotropic drugs on patients with Fetal Alcohol Spectrum Disorder (FASD): a systematic review","volume":"28","author":"Mela","year":"2018","journal-title":"Psychiatry Clin Psychopharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s11920-013-0355-6","article-title":"Antipsychotic and psychostimulant drug combination therapy in attention deficit\/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability","volume":"15","author":"Linton","year":"2013","journal-title":"Curr Psychiatry Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/schbul\/sbq042","article-title":"Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons","volume":"38","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr Bull."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0306-4530(02)00109-9","article-title":"The second-generation \u201catypical\u201d antipsychotics: similar improved efficacy but different neuroendocrine side effects","volume":"28","author":"Tandon","year":"2003","journal-title":"Psychoneuroendocrinology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1192\/bjp.bp.109.076935","article-title":"Treatment with antipsychotics and the risk of diabetes in clinical practice","volume":"197","author":"Kessing","year":"2010","journal-title":"Br J Psychiatry."},{"key":"B12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4088\/JCP.0307e07","article-title":"Antipsychotic medications: metabolic and cardiovascular risk","volume":"68","author":"Newcomer","year":"2007","journal-title":"J Clin Psychiatry."},{"key":"B13","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3389\/fpsyt.2019.00566","article-title":"Nonpharmacological interventions for the treatment of cardiometabolic risk factors in people with schizophrenia-a systematic review","volume":"10","author":"Tumiel","year":"2019","journal-title":"Front Psychiatry."},{"key":"B14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3389\/fnins.2018.00203","article-title":"Clozapine-induced cardiovascular side effects and autonomic dysfunction: a systematic review","volume":"12","author":"Yuen","year":"2018","journal-title":"Front Neurosci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s10597-017-0203-y","article-title":"Monitoring and treating metabolic abnormalities in patients with early psychosis initiated on antipsychotic medications","volume":"54","author":"Bozymski","year":"2018","journal-title":"Community Mental Health J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"852","DOI":"10.2174\/1570159X17666190228113348","article-title":"Association between serum lipids and antipsychotic response in schizophrenia","volume":"17","author":"Kim","year":"2019","journal-title":"Curr Neuropharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/YIC.0000000000000014","article-title":"Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension","volume":"29","author":"Tse","year":"2014","journal-title":"Int Clin Psychopharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00228-015-1807-1","article-title":"Treatment of clozapine-associated weight gain: a systematic review","volume":"71","author":"Whitney","year":"2015","journal-title":"Eur J Clin Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3389\/fpsyt.2014.00105","article-title":"Improving metabolic and cardiovascular health at an early psychosis intervention program in Vancouver, Canada","volume":"5","author":"Fredrikson","year":"2014","journal-title":"Front Psychiatry."},{"key":"B20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s11892-010-0112-8","article-title":"Metabolic syndrome associated with schizophrenia and atypical antipsychotics","volume":"10","author":"Hasnain","year":"2010","journal-title":"Curr Diab Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/schbul\/sbr148","article-title":"Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders\u2013a systematic review and meta-analysis","volume":"39","author":"Mitchell","year":"2013","journal-title":"Schizophr Bull."},{"key":"B22","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ecl.2013.05.006","article-title":"Effects of antipsychotic medications on appetite, weight, and insulin resistance","volume":"42","author":"Deng","year":"2013","journal-title":"Endocrinol Metab Clin North Am."},{"key":"B23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.schres.2007.12.487","article-title":"Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial: prospective data from phase 1","volume":"101","author":"Meyer","year":"2008","journal-title":"Schizophr Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s12170-013-0321-1","article-title":"Management of medication-related cardiometabolic risk in patients with severe mental illness","volume":"7","author":"Lang","year":"2013","journal-title":"Curr Cardiovasc Risk Rep."},{"key":"B26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/YCO.0b013e32835035ca","article-title":"Life expectancy and cardiovascular mortality in persons with schizophrenia","volume":"25","author":"Laursen","year":"2012","journal-title":"Curr Opin Psychiatry."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1080\/14740338.2019.1674809","article-title":"Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia","volume":"18","author":"Marteene","year":"2019","journal-title":"Expert Opin Drug Saf."},{"key":"B28","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.tips.2010.07.002","article-title":"Preclinical models of antipsychotic drug-induced metabolic side effects","volume":"31","author":"Boyda","year":"2010","journal-title":"Trends Pharmacol Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.schres.2008.12.012","article-title":"Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model","volume":"108","author":"Chintoh","year":"2009","journal-title":"Schizophr Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1503\/jpn.170092","article-title":"In male rats, the ability of central insulin to suppress glucose production is impaired by olanzapine, whereas glucose uptake is left intact","volume":"42","author":"Kowalchuk","year":"2017","journal-title":"J Psychiatry Neurosci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e43244","DOI":"10.1371\/journal.pone.0043244","article-title":"Acute peripheral but not central administration of olanzapine induces hyperglycemia associated with hepatic and extra-hepatic insulin resistance","volume":"7","author":"Girault","year":"2012","journal-title":"PLoS ONE."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e53459","DOI":"10.1371\/journal.pone.0053459","article-title":"Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine","volume":"8","author":"Boyda","year":"2013","journal-title":"PLoS ONE."},{"key":"B33","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.neuroscience.2013.10.010","article-title":"Effects of chronic exercise and treatment with the antipsychotic drug olanzapine on hippocampal volume in adult female rats","volume":"255","author":"Barr","year":"2013","journal-title":"Neuroscience."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/j.neuropharm.2011.02.019","article-title":"Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats","volume":"62","author":"Boyda","year":"2012","journal-title":"Neuropharmacology."},{"key":"B35","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1159\/000285780","article-title":"Estrogen replacement reverses olanzapine-induced weight gain and hepatic insulin resistance in ovariectomized diabetic rats","volume":"61","author":"Park","year":"2010","journal-title":"Neuropsychobiology."},{"key":"B36","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1124\/jpet.118.248393","article-title":"AICAR prevents acute olanzapine-induced disturbances in glucose homeostasis","volume":"365","author":"Bush","year":"2018","journal-title":"J Pharmacol Exp Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"14010","DOI":"10.1096\/fj.201901820R","article-title":"AMPK \u03b21 activation suppresses antipsychotic-induced hyperglycemia in mice","volume":"33","author":"Shamshoum","year":"2019","journal-title":"FASEB J."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s40263-013-0115-5","article-title":"Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor","volume":"27","author":"Weston-Green","year":"2013","journal-title":"CNS Drugs."},{"key":"B39","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1177\/0269881118756061","article-title":"Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats","volume":"32","author":"Babic","year":"2018","journal-title":"J Psychopharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1152\/ajpendo.00164.2018","article-title":"Antipsychotics and glucose metabolism: how brain and body collide","volume":"316","author":"Kowalchuk","year":"2019","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"B41","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/jne.12002","article-title":"Peripheral adrenoceptors: the impetus behind glucose dysregulation and insulin resistance","volume":"25","author":"Boyda","year":"2013","journal-title":"J Neuroendocrinol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0893-133X(98)00047-5","article-title":"Mechanism of peripheral noradrenergic stimulation by clozapine","volume":"20","author":"Elman","year":"1999","journal-title":"Neuropsychopharmacology."},{"key":"B43","first-page":"245","article-title":"Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine","volume":"21","author":"Spivak","year":"1998","journal-title":"Clin Neuropharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S0893-133X(97)00073-0","article-title":"Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol","volume":"17","author":"Brown","year":"1997","journal-title":"Neuropsychopharmacology."},{"key":"B45","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/schbul\/sbn104","article-title":"Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: evidence for the involvement of sympathetic regulation","volume":"36","author":"Savoy","year":"2010","journal-title":"Schizophr Bull."},{"key":"B46","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1248\/bpb.b15-00842","article-title":"Mechanism underlying induction of hyperglycemia in rats by single administration of olanzapine","volume":"39","author":"Nagata","year":"2016","journal-title":"Biol Pharmaceut Bull."},{"key":"B47","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.pnpbp.2010.04.024","article-title":"A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model","volume":"34","author":"Boyda","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"B48","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1037\/a0031228","article-title":"Antipsychotic polypharmacy increases metabolic dysregulation in female rats","volume":"21","author":"Boyda","year":"2013","journal-title":"Exp Clin Psychopharmacol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"107717","DOI":"10.1016\/j.neuropharm.2019.107717","article-title":"A comparison of the effects of clozapine and its metabolite norclozapine on metabolic dysregulation in rodent models","volume":"175","author":"Yuen","year":"2020","journal-title":"Neuropharmacology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1017\/S1461145713000795","article-title":"Routine exercise ameliorates the metabolic side-effects of treatment with the atypical antipsychotic drug olanzapine in rats","volume":"17","author":"Boyda","year":"2014","journal-title":"Int J Neuropsychopharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1503\/jpn.110140","article-title":"Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats","volume":"37","author":"Boyda","year":"2012","journal-title":"J Psychiatry Neurosci."},{"key":"B52","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.schres.2009.09.034","article-title":"Sensitivity of the female rat to olanzapine-induced weight gain\u2013far from the clinic?","volume":"116","author":"Weston-Green","year":"2010","journal-title":"Schizophr Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00213-011-2555-2","article-title":"Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters","volume":"221","author":"Davey","year":"2012","journal-title":"Psychopharmacology."},{"key":"B54","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.pnpbp.2013.10.006","article-title":"Antidiabetic-drug combination treatment for glucose intolerance in adult female rats treated acutely with olanzapine","volume":"48","author":"Boyda","year":"2014","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.2196\/jmir.1448","article-title":"Missing data approaches in eHealth research: simulation study and a tutorial for nonmathematically inclined researchers","volume":"12","author":"Blankers","year":"2010","journal-title":"J Med Internet Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2011","journal-title":"Nat Rev Endocrinol."},{"key":"B57","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"Am J Psychiatry."},{"key":"B58","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1248\/bpb1978.11.486","article-title":"A kinetic study of chlorpromazine on the hyperglycemic response in rats. I. effect of chlorpromazine on plasma catecholamines","volume":"11","author":"Sato","year":"1988","journal-title":"J Pharmacobio Dynam."},{"key":"B59","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2147\/TCRM.S117321","article-title":"Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review","volume":"13","author":"Solmi","year":"2017","journal-title":"Ther Clin Risk Manag."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1248\/bpb.b18-00195","article-title":"Clozapine-induced acute hyperglycemia is accompanied with elevated serum concentrations of adrenaline and glucagon in rats","volume":"41","author":"Nagata","year":"2018","journal-title":"Biol Pharm Bull."},{"key":"B61","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0165-1781(93)90016-A","article-title":"Clozapine response and plasma catecholamines and their metabolites","volume":"46","author":"Green","year":"1993","journal-title":"Psychiatry Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/BF01273320","article-title":"Blood biogenic amines during clozapine treatment of early-onset schizophrenia","volume":"104","author":"Schulz","year":"1997","journal-title":"J Neural Transm."},{"key":"B63","doi-asserted-by":"publisher","first-page":"S508","DOI":"10.1097\/01.CCM.0000278047.06965.20","article-title":"Glucose metabolism and catecholamines","volume":"35","author":"Barth","year":"2007","journal-title":"Crit Care Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/HJH.0b013e328048d004","article-title":"The sympathetic nervous system and the metabolic syndrome","volume":"25","author":"Mancia","year":"2007","journal-title":"J Hypertension."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e107116","DOI":"10.1371\/journal.pone.0107116","article-title":"An evaluation of the effects of the novel antipsychotic drug lurasidone on glucose tolerance and insulin resistance: a comparison with olanzapine","volume":"9","author":"Wu","year":"2014","journal-title":"PLoS ONE."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e22662","DOI":"10.1371\/journal.pone.0022662","article-title":"A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers","volume":"6","author":"Albaugh","year":"2011","journal-title":"PLoS ONE."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1373\/clinchem.2008.107193","article-title":"Neuronal source of plasma dopamine","volume":"54","author":"Goldstein","year":"2008","journal-title":"Clin Chem."},{"key":"B68","doi-asserted-by":"publisher","first-page":"5570","DOI":"10.1210\/en.2010-0745","article-title":"Minireview: new roles for peripheral dopamine on metabolic control and tumor growth: let's seek the balance","volume":"151","author":"Rub\u00ed","year":"2010","journal-title":"Endocrinology."},{"key":"B69","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.schres.2015.08.015","article-title":"Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia","volume":"169","author":"Schreiner","year":"2015","journal-title":"Schizophr Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1126\/science.867049","article-title":"Suppression of sympathetic nervous system during fasting","volume":"196","author":"Young","year":"1977","journal-title":"Science."},{"key":"B71","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1172\/JCI110976","article-title":"Effect of dietary fat on sympathetic nervous system activity in the rat","volume":"72","author":"Schwartz","year":"1983","journal-title":"J Clin Invest."},{"key":"B72","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/269615a0","article-title":"Stimulation of the sympathetic nervous system during sucrose feeding","volume":"269","author":"Young","year":"1977","journal-title":"Nature."},{"key":"B73","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/j.1768-322X.2004.tb01424.x","article-title":"alpha2-adrenergic receptor subtypes - novel functions uncovered in gene-targeted mouse models","volume":"96","author":"Brede","year":"2004","journal-title":"Biol Cell."},{"key":"B74","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1037\/a0022258","article-title":"An index of relative central \u03b1-adrenergic receptor antagonism by antipsychotic medications","volume":"19","author":"Minzenberg","year":"2011","journal-title":"Exp Clin Psychopharmacol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/0006-8993(86)91411-3","article-title":"Locus coeruleus norepinephrine-containing neurons: effects produced by acute and subchronic treatment with antipsychotic drugs and amphetamine","volume":"362","author":"Ramirez","year":"1986","journal-title":"Brain Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.1748-1716.2007.01807.x","article-title":"A physiological view of the central and peripheral mechanisms that regulate the release of catecholamines at the adrenal medulla","volume":"192","author":"de Diego","year":"2008","journal-title":"Acta Physiol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"104400","DOI":"10.1016\/j.psyneuen.2019.104400","article-title":"Direct effects of antipsychotic drugs on insulin, energy sensing and inflammatory pathways in hypothalamic mouse neurons","volume":"109","author":"Kowalchuk","year":"2019","journal-title":"Psychoneuroendocrinology."},{"key":"B78","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0014-2999(99)00005-9","article-title":"Pharmacological profile of neuroleptics at human monoamine transporters","volume":"368","author":"Tatsumi","year":"1999","journal-title":"Eur J Pharmacol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1139\/y11-102","article-title":"Influence of gender and estrous cycle on plasma and renal catecholamine levels in rats","volume":"90","author":"Gomes","year":"2012","journal-title":"Can J Physiol Pharmacol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2020.617428\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T15:45:22Z","timestamp":1669909522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2020.617428\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":80,"alternative-id":["10.3389\/fpsyt.2020.617428"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2020.617428","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,1]]},"article-number":"617428"}}